We postulate that the increased immunogenicity of AZA pre-treated AML cells enhances the downstream signaling events of the CAR T cells by prolonging phosphorylation of molecules associated with T cell activation and function thereby preventing the induction of CTLA-4 on the surface of the CAR T cells. This evidence concerns the gene CTLA4 and acute myeloid leukemia.